Cancer of Unknown Primary Site Recruiting Phase 2 Trials for Tegafur (DB09256)

IndicationStatusPhase
DBCOND0089665 (Cancer of Unknown Primary Site)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01845337Study to Compare Cardiovascular Side Effects of Teysuno Versus CapecitabineTreatment